COVID-19 Among Children With Chronic Renal Diseases in Qatar

CompletedOBSERVATIONAL
Enrollment

1,300

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Chronic Kidney DiseasesCOVID-19 InfectionAcute Kidney InjuryChronic Renal Failure in ChildrenCOVID-19 Pandemic
Interventions
OTHER

Medical records review

"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."

OTHER

Medical records review

Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.

Trial Locations (1)

3050

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT05275595 - COVID-19 Among Children With Chronic Renal Diseases in Qatar | Biotech Hunter | Biotech Hunter